Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 14/20 | 0.52 |
| ▸ | CNR1 | P21554 | 9/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.48 |
| ▸ | RAB7A | P51149 | 1/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPRB | P23467 | 1/20 | 0.47 |
| ▸ | PTPRE | P23469 | 1/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457693 | 0.86 | KMT2A (0.60) | CFTRCNR2CNR1KMT2ANOD1 | |
| SCHEMBL5449174 | 0.82 | CFTR (0.55) | CFTRCNR2CNR1KMT2ANOD1 | |
| SCHEMBL5459324 | 0.79 | CFTR (0.55) | CFTRCNR2CNR1KMT2ANOD1 | |
| SCHEMBL5455947 | 0.78 | MEN1 (0.65) | CFTRCNR2CNR1KMT2ARAB7A | |
| SCHEMBL5451008 | 0.76 | CFTR (0.59) | CFTRCNR2CNR1KMT2ARAB7A | |
| SCHEMBL5449075 | 0.75 | CFTR (0.66) | CFTRCNR2CNR1KMT2ARAB7A | |
| SCHEMBL5453258 | 0.74 | FLT3 (0.73) | CFTRCNR2KMT2ARAB7APTPRC | |
| SCHEMBL5453252 | 0.74 | FLT3 (0.73) | CFTRCNR2KMT2ARAB7APTPRC | |
| SCHEMBL5459985 | 0.74 | CFTR (0.57) | CFTRKMT2ARAB7APTPRCPTPN2 | |
| SCHEMBL5460547 | 0.74 | MEN1 (0.58) | CFTRCNR2KMT2ARAB7APTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | CFTR 2030/4885CNR2 2272/4885CNR1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.